Angiocrine Bioscience is a private, clinical stage engineered cell therapy company harnessing the power of genetically modified human endothelial cells to regenerate tissues, restore function and rejuvenate patients with serious medical conditions. Our team is developing a pipeline of proprietary engineered endothelial cell (E-CEL® ) therapies for treating multiple life-threatening hemato-oncologic and immunologic conditions, as well as, regenerating tissues and organs that have been injured or damaged by diseases.
Location: United States, California, San Diego
Employees: 11-50
Total raised: $15M
Founded date: 2012
Investors 2
| Date | Name | Website |
| - | Cobro Vent... | cobroventu... |
| - | Good Growt... | goodgrowth... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 18.12.2022 | Grant | $15M | - |
Mentions in press and media 3
| Date | Title | Description | Source |
| 12.03.2021 | Angiocrine Bioscience Announces Oral Presentation of AB-205 ... | SAN DIEGO, March 12, 2021 /PRNewswire/ -- Angiocrine Bioscience Inc., a clinical-stage biopharmace... | prnewswire... |
| 05.02.2021 | Angiocrine Bioscience Announces Oral Presentation of Intrave... | SAN DIEGO, Feb. 5, 2021 /PRNewswire/ -- Angiocrine Bioscience Inc., a clinical-stage biopharmaceut... | prnewswire... |
| 04.12.2020 | Angiocrine Bioscience Announces Oral Presentation of AB-205 ... | SAN DIEGO, Dec. 4, 2020 /PRNewswire/ -- Angiocrine Bioscience Inc., a clinical-stage biopharmaceut... | prnewswire... |